BBC
Virtus LifeSci Biotech Clinical Trials ETFBBC Fund Description
BBC tracks an equally weighted index of US-listed biotech companies with lead drugs in various phases of clinical trials.
BBC Factset Analytics Insight
BBC charges a stiff fee for focused exposure to biotech companies with lead drugs still in various phases of clinical trials. Given the low historical success rates in clinical trials, the fund is a high-risk and high-reward bet on a small subset of biotech companies. As such, if you're looking for broad biotech exposure, you won't find it in BBC, which carries an elevated beta and ends up with a basket for primarily small- and micro-cap stocks. That micro-heavy basket means that larger traders might face some obstacles to efficient block execution. Retail traders should likewise handle with care, as volume is weak and spreads can be sizeable. BBC has attracted middling investor interest, but closure risk cannot be dismissed.
BBC MSCI ESG Analytics Insight
Virtus LifeSci Biotech Clinical Trials ETF has an MSCI ESG Fund Rating of B based on a score of 2.80 out of 10. The MSCI ESG Fund Rating measures the resiliency of portfolios to long-term risks and opportunities arising from environmental, social, and governance factors. ESG Fund Ratings range from best (AAA) to worst (CCC). Highly rated funds consist of companies that tend to show strong and/or improving management of financially relevant environmental, social and governance issues. These companies may be more resilient to disruptions arising from ESG events.
The fund’s Peer Rank reflects the ranking of a fund’s MSCI ESG Fund Quality Score against the scores of other funds within the same peer group, as defined by the Thomson Reuters Lipper Global Classification. Virtus LifeSci Biotech Clinical Trials ETF ranks in the 7th percentile within its peer group and in the 11st percentile within the global universe of all funds covered by MSCI ESG Fund Ratings.
BBC Charts And Performance
-
1 Month
-
3 Months
-
YTD
-
1 Year
-
3 Years
-
5 Years
-
Max
-
1 Month
-
3 Months
-
YTD
-
1 Year
-
3 Years
-
5 Years
-
Max
-
BBC Summary Data
BBC Portfolio Data
BBC Index Data
BBC Portfolio Management
BBC Tax Exposures
BBC Fund Structure
BBC Factset Analytics Block Liquidity
This measurement shows how easy it is to trade a $1 million USD block of BBC. BBC is rated a 4 out of 5.
BBC Tradability
BBC Sector/Industry Breakdown
BBC
BBC Top 10 Holdings[View All]
BBC Countries
BBC
BBC Regions
BBC
BBC Economic Development
BBC
BBC Performance Statistics
BBC MSCI ESG Ratings
BBC Benchmark Comparison Summary
BBC
BBC Benchmark Comparison Market Cap Size
BBC
The data and information contained herein is not intended to be investment or tax advice. A reference to a particular investment or security, a credit rating, or any observation concerning a security or investment provided in the ETF.com Service is not a recommendation to buy, sell, or hold such investment or security or to make any other investment decisions. You should not use such information for purposes of any actual transaction without consulting an investment or tax professional.
ETF.com DOES NOT TAKE RESPONSIBILITY FOR YOUR INVESTMENT OR OTHER ACTIONS NOR SHALL ETF.com HAVE ANY LIABILITY, CONTINGENT OR OTHERWISE, FOR THE ACCURACY, COMPLETENESS, TIMELINESS, OR CORRECT SEQUENCING OF ANY INFORMATION PROVIDED BY ETF.com OR FOR ANY DECISION MADE OR ACTION TAKEN BY YOU IN RELIANCE UPON SUCH INFORMATION OR ETF.com.
[ETF.com DOES NOT PROVIDE ANY RESEARCH OPINIONS.] ETF.com MAKES NO REPRESENTATIONS ABOUT THE SUITABILITY OF THE INFORMATION, PRODUCTS OR SERVICES CONTAINED HEREIN. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS.
Data provider:
Terms of Use
MSCI ESG Research LLC’s ("MSCI ESG") Fund Metrics products (the "Information") provide environmental, social and governance data with respect to underlying securities within more than 24,000 multi-asset class Mutual Funds and ETFs globally. MSCI ESG is a Registered Investment Adviser under the Investment Advisers Act of 1940. MSCI ESG materials have not been submitted to, nor received approval from, the US SEC or any other regulatory body. None of the Information constitutes an offer to buy or sell, or a promotion or recommendation of, any security, financial instrument or product or trading strategy, nor should it be taken as an indication or guarantee of any future performance, analysis, forecast or prediction. None of the Information can be used to determine which securities to buy or sell or when to buy or sell them. The Information is provided "as is" and the user of the Information assumes the entire risk of any use it may make or permit to be made of the Information.